Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
-0.21 (-4.42%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.46 - 4.79
52 week 1.86 - 6.80
Open 4.79
Vol / Avg. 5.86M/4.49M
Mkt cap 1.08B
P/E     -
Div/yield     -
EPS -0.92
Shares 227.22M
Beta 2.31
Inst. own 71%
Feb 23, 2016
Q4 2015 Exelixis Inc Earnings Release - Tentative - 4:00PM EST - Add to calendar
Feb 10, 2016
Exelixis Inc at Leerink Partners Global Healthcare Conference - 11:05AM EST - Add to calendar
Nov 17, 2015
Exelixis Inc at Stifel Healthcare Conference
Nov 10, 2015
Q3 2015 Exelixis Inc Earnings Call - Webcast
Nov 10, 2015
Q3 2015 Exelixis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -482.69% -1069.42%
Operating margin -363.11% -893.86%
EBITD margin - -854.00%
Return on average assets -62.34% -64.61%
Return on average equity - -
Employees 98 -
CDP Score - -


210 E Grand Ave
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Company's other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Christopher J. Senner Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Discovery Research, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Jeffrey J Hessekiel Executive Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Pamela A. Simonton J.D. Executive Vice President
Age: 64
Bio & Compensation  - Reuters
Deborah Burke Senior Vice President - Finance, Controller
Age: 59
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq Independent Director
Age: 71
Bio & Compensation  - Reuters